A Long-term Trial of EB-1020 in Adult Patients With ADHD

Key facts

Sponsor

Otsuka Pharmaceutical Co., Ltd.

Principal Investigator

Nobuhito Sanada

Otsuka Pharmaceutical Co., Ltd.

Intervention

EB-1020 (Centanafadine) 164.4 mg(drug)

Enrollment

180 target

Eligibility

18-55 years · All sexes

Timeline

2025 – 2027

Study locations (1)

• Maynds Tower Mental Clinic, Tokyo, Japan

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Cap myopathy

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT07359287
  Impact of a Multimodal Intervention on Antibiotic Prescribing for Respiratory Infections in Primary Care
  University Hospital, Caen
• RECRUITINGNANCT07325344
  Active Locomotion of Magnetically Controlled Capsule Endoscopy in the Small Bowel: A Feasibility Study
  Shandong University
• ACTIVE NOT RECRUITINGNANCT07151261
  Ashwagandha for Nighttime Waking
  National University of Natural Medicine
• RECRUITINGNANCT07268365
  Is Cap Assisted Endoscopy Useful in Acute Upper Gastrointestinal Bleeding ?
  Centre Hospitalier Universitaire, Amiens
• RECRUITINGPHASE2, PHASE3NCT07086313
  A Trial to Evaluate the Efficacy and Safety of EB-1020 in Pediatric Patients With ADHD
  Otsuka Pharmaceutical Co., Ltd.
• RECRUITINGPHASE4NCT07193277
  Butylphthalide for Cognitive Impairment in Elderly Patients With Focal Epilepsy
  First Affiliated Hospital of Wenzhou Medical University
• ACTIVE NOT RECRUITINGNCT06733337
  A Study to Learn About the Safety of TALZENNA in People With Prostate Cancer.
  Pfizer
• RECRUITINGNANCT07033208
  Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance
  Massachusetts General Hospital

See all trials for Cap myopathy →